CTOs on the Move

Savara Pharmaceuticals

www.savarapharma.com

 
Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.savarapharma.com
  • 6836 Bee Cave Road Building 3, Suite 200
    Austin, TX USA 78746
  • Phone: 512.961.1891

Executives

Name Title Contact Details

Funding

Savara Pharmaceuticals raised $18.54M on 12/17/2015
Savara Pharmaceuticals raised $47M on 10/26/2017
Savara Pharmaceuticals raised $26.8M on 01/15/2020
Savara Pharmaceuticals raised $130M on 03/11/2021

Similar Companies

MAP Pharmaceuticals

MAP Pharmaceuticals is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Robert E Mason Co

Robert E Mason Co is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Huber Kältemaschinen

Temperature Control Solutions for Laboratory and Production from -125 °C to +425 °C

Processo Partners, In

Processo Partners, In is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.